VNU cancels $7 billion acquisition of IMS, cites shareholders

Share this article:

Dutch publisher VNU has terminated its $7 billion plan to take over IMS Health, both companies confirmed.
"Several of VNU's major shareholders have made it clear, for a variety of reasons, they did not want to pursue any large merger at this time," said IMS CEO/president David Carlucci in a statement.
"While we regret that the merger with VNU will not happen, our business is strong." VNU CEO Rob van den Bergh said, "Having heard the views of our shareholders, it became clear that it
would not be possible for us to proceed with the proposed merger." In a statement announcing the cancellation of the deal, van den Bergh added that he planned to step down from his CEO post. It was unclear at press time whether his resignation was directly related to the dissolution of the merger.
VNU has agreed to reimburse IMS $15 million for its actual out-ofpocket costs related to merger planning, and an additional $45 million should VNU be acquired in the next 12 months. For its part, IMS has agreed to return the $15 million payment to VNU if IMS is acquired in
the next 12 months. Since the deal was announced in July, VNU shareholders reacted negatively to the merger plan. Nearly half of VNU shareholders said they wouldn't vote for the deal under any circumstances, essentially dooming the deal before it could reach a full vote.


 

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union